Brind.
  1. Indivior announced strategic corporate developments on July 28, 2025, including executive appointments, market strategy shifts, and FDA approval for updated labeling of SUBLOCADE.

Indivior cancelled its secondary listing on the London Stock Exchange.

1 report, 1 independent Updated Jul 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Indivior cancelled its secondary listing on the London Stock Exchange.

Who's involved

What this event is mainly about
Indivior

Keep exploring

Part of

Indivior announced strategic corporate developments on July 28, 2025, including executive appointments, market strategy shifts, and FDA approval for updated labeling of SUBLOCADE. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • PR NewswireIndivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNews